ETON

Eton Pharmaceuticals, Inc. - 2025 Annual Report (10-K) Summary

Business Context and Reporting Period

This filing is the Annual Report on Form 10-K for Eton Pharmaceuticals, Inc. for the fiscal year ended December 31, 2025. Eton is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The company operates as a single reporting segment and is classified as a non-accelerated filer and a smaller reporting company.

As of December 31, 2025, Eton commercialized eight products: INCRELEX, ALKINDI SPRINKLE, KHINDIVI, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The company also maintains a pipeline of five late-stage product candidates, including ET-600 (Diabetes Insipidus), which had a PDUFA target action date of February 25, 2026.

Key Financial Metrics

Note: Debt figures include current and long-term portions net of discounts and accrued fees. Working capital is calculated as Total Current Assets minus Total Current Liabilities.

Material Changes vs. Prior Period

• Revenue Growth: Total net revenues increased 105% year-over-year, driven primarily by a 99% increase in product sales and royalties ($76.7M vs. $38.5M). This growth was attributed to increased sales volumes of INCRELEX, ALKINDI SPRINKLE, and GALZIN.
• Licensing Revenue: Licensing revenue surged to $3.3M from $0.5M in 2024. This included $1.8M from out-licensing INCRELEX rights outside the U.S. and a $1.5M milestone from the divestiture of DS-200.
• Cost of Sales: Increased to $37.2M from $15.6M, largely due to higher product sales volume and commissions related to the INCRELEX out-licensing. This resulted in a gross margin compression from 60.0% to 53.5%.
• Operating Expenses:
  • R&D Expenses: Rose to $7.8M from $3.3M, primarily due to a $2.2M NDA filing fee for ET-600 and development costs for ET-700 and ET-800.
  • G&A Expenses: Increased to $35.8M from $22.8M, driven by higher advertising/promotional expenses, stock-based compensation, and increased headcount.
• Acquisitions: The company completed the acquisition of INCRELEX in December 2024 and GALZIN in December 2024 (commercialized March 2025), significantly impacting inventory and intangible asset balances.

Guidance, Outlook, and Risks

Outlook and Catalysts:

• ET-600: The NDA was accepted for review with a PDUFA date of February 25, 2026. Launch inventory production is scheduled for Q1 2026.
• Amglidia: Licensing agreement signed for U.S. rights to treat neonatal diabetes mellitus.
• Liquidity: Management believes cash and cash equivalents of $25.9M are sufficient to fund operations for at least the next 12 months.

Key Risks and Contingencies:

• Regulatory Approval: Success depends on FDA approvals for pipeline candidates (ET-600, Amglidia, etc.). Failure to obtain approval would limit revenue generation.
• 505(b)(2) Pathway: Reliance on this regulatory pathway carries risks of patent litigation and potential delays if the FDA requires additional data.
• Reimbursement: The Inflation Reduction Act (IRA) and Medicare reforms may impact net prices and demand. The company notes minimal current impact due to low Medicare patient volume but monitors potential future changes.
• Supply Chain: The company relies entirely on third-party contract manufacturers (CMOs). Disruptions or quality issues at CMOs could halt commercialization.
• Customer Concentration: AnovoRx represented 84.6% of net revenues in 2025, creating significant concentration risk.

Investor Verification Checklist

• ET-600 Approval Status: Verify the outcome of the FDA PDUFA decision scheduled for February 25, 2026, as this is a critical near-term catalyst.
• INCRELEX Integration: Monitor sales performance and margin trends post-acquisition, specifically regarding the impact of out-licensing commissions on gross margin.
• Debt Covenants: Review the terms of the SWK credit agreement ($30M facility) to ensure compliance with financial covenants and understand the impact of the 5.0% exit fee and variable interest rates (SOFR + 6.75%).
• Customer Concentration: Assess the stability of the relationship with AnovoRx, which accounted for the vast majority of revenue and accounts receivable.
• Inventory Step-Up: Understand the $5.1M inventory step-up expense recognized in 2025 related to the INCRELEX acquisition and its impact on future cost of sales.